Psychedelics Today
Psychedelics Today is the planetary leader in psychedelic education, media, and advocacy. Covering up-to-the-minute developments and diving deep into crucial topics bridging the scientific, academic, philosophical, societal, and cultural, Psychedelics Today is leading the discussion in this rapidly evolving ecosystem.
info_outline
PT 662 - Jordan Kronick - PEAKING
10/21/2026
PT 662 - Jordan Kronick - PEAKING
Joe sits down with Jordan Kronick, the director, writer, and producer of Peaking: Psychedelics and the Pursuit of Happiness, a new documentary now rolling out in theaters city by city. The film covers six substances (psilocybin, LSD, ayahuasca, ibogaine, MDMA, and 5-MeO-DMT from the toad) and puts cameras inside the dosing room. Viewers follow first-time users before, during, and after their experiences. Jordan’s path into this work goes back to 2003, when he produced Ecstasy Rising for Peter Jennings at ABC News. That primetime documentary challenged the government’s “holes in your brain” campaign, and the scientist behind the flawed study retracted it before the film aired. Rick Doblin credits that moment with helping open the door to MAPS’ first MDMA for PTSD research. Joe and Jordan talk about brain injury in pro sports, including Daniel Carcillo’s story and a planned Johns Hopkins study on concussions. They cover the film’s “big tent” approach and how Jordan found subjects through Heroic Hearts Project and Beond in Cancun. Joe raises his concerns about toad sustainability and safety. From there they get into the drug war’s echoes from the 1960s to the 1980s, the Starck Club in Dallas, and Michael Clegg, the man credited with naming ecstasy. They close on today’s bipartisan support for psychedelics, the road to FDA approval for Compass Pathways and Lykos, and the strange prospect of psychedelics becoming federally legal before cannabis. About Jordan Kronick Jordan Kronick is a documentary filmmaker who began his career at ABC News as a producer for Peter Jennings Reporting, where he made Ecstasy Rising (2004). He later worked at HBO’s Real Sports with Bryant Gumbel, reporting on psychedelics in sports in 2020. Peaking premiered in June 2026 at Dances With Films at the TCL Chinese Theatre in Los Angeles. In this episode Making a six-substance documentary in 19 months, from March 2024 to October 2025 How Ecstasy Rising debunked the MDMA neurotoxicity campaign Psychedelics, concussions, and CTE in the NHL, NFL, and MMA Daniel Carcillo and a planned Johns Hopkins study on brain repair Following veterans to the Amazon with Heroic Hearts Project Ibogaine for opioid addiction at Beond in Cancun Toad in the California desert, plus Joe’s caution on sustainability and the myth of ancestral use Clinical versus experiential approaches to psychedelic work How the 1980s MDMA crackdown mirrored the 1960s The Starck Club, Michael Clegg, and why ecstasy spread so fast Rick Perry, veterans, and bipartisan support for ibogaine Compass Pathways, Lykos, patents, and what FDA approval would and wouldn’t legalize Psychedelics leapfrogging cannabis Chapters 00:00 Intro 04:15 Meet Jordan Kronick and Peaking 05:38 From the LA premiere to a city by city theatrical release 08:39 Ecstasy Rising and the “holes in your brain” campaign 13:01 Following the renaissance, and psychedelics in sports at HBO 19:33 Can psychedelics repair the brain? 22:19 Designing a “big tent” film 26:05 Witnessing transformation in the dosing room 28:10 Finding the subjects 32:47 Toad: wild edges and real concerns 38:46 Access in Oregon and Colorado 41:12 The drug war, 1960s and 1980s 47:58 Rick Doblin’s role 49:30 Archival footage and early research 51:08 Michael Clegg, Texas, and the Starck Club 56:30 Bipartisan support and ibogaine in Texas 58:16 What’s next with the FDA 1:02:36 Psychedelics before cannabis? 1:04:40 Where to see Peaking
/episode/index/show/psychedelicstoday/id/43384884
info_outline
PT 661 - Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
10/07/2026
PT 661 - Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper has spent decades working at the intersection of drug policy, public health, harm reduction, education, and psychedelics. In this episode, Joe Moore talks with Tupper about his early work with DanceSafe and drug checking, British Columbia’s overdose crisis and experiment with decriminalization, and what the psychedelic field can learn from decades of harm reduction work and research. They also dig into Tupper’s academic work on psychedelics and education, the idea of entheogens as “plant teachers,” ayahuasca policy in Canada, problems with conventional drug education, and the limits of treating psychedelics exclusively as medicines. The conversation eventually widens into a bigger question: What does it actually mean to educate people well about drugs, altered states, and consciousness? Enjoy the show. Disclaimer: Intro and promotional audio in this episode were generated using synthetic voice technology. The interview itself is unaltered. Show Notes (Machine Generated) Kenneth Tupper’s career has followed two parallel tracks: psychedelic scholarship and public health. Long before the current psychedelic resurgence, he was studying the idea of entheogens as tools for learning and examining how Indigenous traditions understand plants such as ayahuasca, peyote, and psilocybin as teachers. At the same time, work with DanceSafe and early pill testing drew him into harm reduction and eventually into more than two decades of public-health and drug-policy work in British Columbia. Tupper and Joe revisit the early history of drug checking and the logic behind harm reduction: if people are going to use drugs, providing accurate information and reducing preventable risks can save lives. That discussion leads into supervised consumption sites, pharmaceutical alternatives to illicit opioids, fentanyl, the toxic drug supply, naloxone, and the difficult reality of people surviving overdoses while sustaining hypoxic or anoxic brain injuries. They also examine British Columbia’s experiment with drug decriminalization. Tupper describes the limits of decriminalizing possession without simultaneously addressing housing, healthcare, treatment options, the illicit supply, and other social conditions. The conversation contrasts British Columbia with Portugal and explores why drug policy interventions cannot easily be transplanted from one social and historical context into another. From there, the discussion turns directly toward psychedelics. Tupper argues that psychedelic public health should involve more than clinical treatment. Psychedelics may have roles in health promotion, community building, education, rites of passage, and helping people who are not necessarily diagnosed with a psychiatric disorder. At the same time, wider access creates a need for better harm-reduction information, screening, preparation, and attention to set, setting, and the larger social environment in which psychedelic experiences occur. Drug education becomes one of the central themes of the episode. Tupper compares the history of drug education with sex education and argues that drug education has remained unusually tied to prescribed behavioral outcomes—particularly abstinence. Rather than simply telling young people what not to do, he asks what genuine education about drugs might look like when curiosity, experimentation, risk, pleasure, and real-world access are acknowledged. That question connects back to Tupper’s longstanding work on what he calls entheogenic education. Drawing on educational thinkers including John Dewey and Lev Vygotsky, he discusses psychedelics as potential “cognitive tools” and considers how experiential education might offer models beyond conventional schooling. Joe and Tupper also discuss how AI may force an even deeper reconsideration of education when reading, writing, calculation, and information retrieval can increasingly be outsourced to machines. The final part of the conversation focuses heavily on ayahuasca. Tupper discusses his doctoral research into the Canadian government’s handling of a Santo Daime religious exemption, the difficulty of fitting ceremonial entheogen use into modern drug-control frameworks, and tensions between religious, biomedical, Indigenous, and public-health ways of understanding ayahuasca. Joe and Tupper also examine consent and safety around ayahuasca admixtures. Traditional brews can vary significantly in composition, raising difficult questions about informed consent, standardization, cultural autonomy, and how Western participants can make informed decisions when entering practices developed in very different cultural contexts. The episode closes with a broader discussion of knowledge itself. Tupper argues for taking scientific methods seriously without assuming that Western science represents the only legitimate way of knowing. As psychedelics, Indigenous knowledge, AI, ecological crisis, and modern medicine increasingly intersect, he sees questions of epistemology—how we know what we know—as becoming increasingly important. In This Episode Kenneth Tupper’s path from psychedelic scholarship into harm reduction and public health Why he adopted the term entheogen in his early academic work Jonathan Ott and the politics of psychedelic language The early days of DanceSafe and pill testing Why drug checking became a public-health intervention Supervised consumption sites and their limitations Fentanyl and British Columbia’s toxic drug crisis Naloxone, overdose survival, and hypoxic brain injury Why addiction cannot be reduced to a simple pharmacological model British Columbia’s experiment with drug decriminalization Why the Portuguese model cannot simply be copied elsewhere Psychedelics as one tool within a larger public-health system Psychedelic access in Canada compared with Colorado and Oregon The risks of over-medicalizing psychedelics Psychedelics for health promotion rather than only diagnosed illness Why traditional drug education has struggled Drug education versus sex education Abstinence, harm reduction, and genuine education John Dewey, experiential learning, and progressive education Lev Vygotsky and the idea of cognitive tools What AI may do to conventional schooling Psychedelics as educational tools and rites of passage Dennis McKenna’s influence on Tupper’s ayahuasca research Santo Daime and religious exemptions for ayahuasca in Canada Why ayahuasca does not fit neatly into conventional drug policy Consent and transparency around ayahuasca admixtures Safety, lineage, power, and sexual misconduct in ceremonial settings Indigenous and biomedical models of healing Science, epistemology, and multiple ways of knowing Tupper’s experience with ibogaine Why he coined the term “intonicated” Links Kenneth Tupper Kenneth Tupper – Research & Publications Intonicated Podcast — Tupper’s podcast on altered states, healing, learning, and wellbeing. DanceSafe Transcript Joe Moore (00:11): Everybody, welcome back to Psychedelics Today. Joe Moore here, joined by Kenneth Tupper. How are you doing today? Kenneth Tupper (00:17): Great. Nice to be here. Thanks, Joe. Joe Moore (00:19): Absolutely. So you're joining us today from the glorious Vancouver Island, is that right? Kenneth Tupper (00:25): Correct. Victoria, British Columbia, traditional territories of the Songhees, Esquimalt, and Songhees First Nations. Joe Moore (00:33): Gorgeous. Thank you. And I'm... I'm going to try to introduce you a little bit here, but we'll have you kind of tee yourself up a bit. But we met at the Psychedelic Safety Institute Summit at UC Berkeley. Stacey Wallen helped put that together with a few others. It was a pretty big event. And maybe we can chat about this later, but it was the first ever event I went to that felt like AI was a backbone component to the event, which was fascinating. I don't, you know, at times uncomfortable, but also like, you know, I was respecting just how skillfully it was employed. But let's talk about you. You've got a long career in harm reduction. You've been able to volunteer not only with DanceSafe, but many other harm reduction groups. And then you spent some time in the British Columbian government doing harm reduction work. Is that right? Kenneth Tupper (01:28): Over twenty years, yep. Joe Moore (01:31): That's a bit. So thanks for all that hard work. How do you like to describe your career, your position in the ecosystem here? Kenneth Tupper (01:42): So predating my public health career was an academic interest in psychedelics, or the term that I used originally was entheogen. And not in the health or healing space, but education. I was interested in advancing some understanding of the metaphor of plant teachers in traditional indigenous uses of plants like ayahuasca, peyote, or psilocybin mushrooms. And then from that got into accidentally harm reduction. I didn't even know the term at the time, but, uh, working with dance safe, running a dance safe chapter, uh, and getting involved in pill testing. And then through that, through connections, got into public health, um, and continued to sort of advance the academic work that I was doing on the side, but it was sort of two parallel trajectories, but both in the area of sort of drug policy. So my PhD, uh, ended up being on ayahuasca and the sort of public policy implications of its emergence of the Amazon. But my work in government was in the harm reduction space, prevention writ large, but prevention of what? This is one of the questions I asked, you know, preventing harms or preventing use or preventing quote abuse, a term that I find problematic for a number of reasons. And yeah, and then also got into some clinical related work like opiate agonist treatment, methadone, which back in the day was kind of debated whether it's more of a treatment or a harm reduction intervention. Some people fell on one side or the other. In some ways it's both. Yeah, so that kind of defines, and then the last ten years working primarily on the toxic drug crisis or opioid overdose crisis here in British Columbia, which is one of the hardest hit provinces in Canada. And then still sort of keeping my toe in the world of psychedelics in and out, more out for the past number of years for a variety of more personal reasons, but coming back in and that Psychedelic Safety Institute Summit was part of that. And yeah, that's me in a nutshell. Joe Moore (03:50): So I have a confession i'll make on this show for the first time ever i am just now for the first time reading jonathan ott's pharmacotheon and i'm a bit embarrassed um that i'm just getting around to it now because his analysis uh commentary is just writing is so helpful and good and he he uh was one of the team that helped push this word and theogen And I'm just, right before this, I was working through his description of, you know, why entheogen as a term. I find it interesting. And I don't know, I just, anything that smells a little religious, I push back from, as if psyche doesn't have those religious connotations anyway. But, you know, in our strange times, I kind of use the psychedelic term as kind of like, in a way, to just be loud and proud about it, kind of leveraging gay rights movement kind of logic a bit. But I don't know, and sorry to go down something so banal as defining why you might wanna use a term like entheogen, but could you talk about that a little bit? Kenneth Tupper (05:07): Absolutely. And, you know, I could talk all afternoon about this. Language is sort of the world in which I swam academically. Critical discourse analysis was my sort of methodology for looking at public policy and the sort of way that language is invested with power overtly in public policy and law. of course there's micro powers and sort of everyday everyday language and discourse but for me personally the term entheogen was more sort of politically convenient in advancing an interest in this topic in through university structures in the late nineties early two thousands when the word psychedelic i mean being in the closet was the safe place to be at the time uh being more out was was sort of risky uh endeavor in terms of you know getting academic respectability um and i i found the term entheogen very helpful. So I'd come across it and reading Jonathan Ott's work and others at the time. I found it really helpful for framing traditional indigenous uses of plants versus the more sort of white powder application of a biomedical paradigm or psychotherapeutic paradigm. And I still actually find it a helpful heuristic of distinguishing entheogenic healing from psychedelic medicine with those sort of broad separations. Of course, there's lots of intersections and hybridities across them as well. And in some ways, you know, it's resonant of the failure of modern Western medicine to recognize the spiritual dimension in healing and health, something that I would argue in many most traditional indigenous cultures is seen to be, you know, synonymous, that those two concepts are completely intertwined, that the shaman functions both as a priest and And they've got the power of healing medicine man, as well as that spiritual intersection. So for me personally, that was why I ran with it. And there's a nice assonance with entheogenic education. Joe Moore (07:13): Well, at a later date, I'd have to dig in more on this. But I want to focus on this interesting harm reduction thread. it's cool it's really important to me as well um i jokingly almost renamed the show drug war today a few times like i just it's all i really wanted to talk about um for a lot of reasons uh so back in the day you called it pill checking like it wasn't drug testing testing pill testing that's interesting and it was just like ravers or was it all sorts of people that you were supporting Kenneth Tupper (07:51): The places we were doing it was at raves as they were called you know big electronic dance parties and my understanding is that's kind of the well there was deeper origin i think back in the early seventies there was some what we'd call drug checking happening in places like uh hate ashbury um free clinic and so there's some very sort of early moves towards it but it really kind of got lost in the shuffle for for many years and sort of the reagan era war on drugs but then With the rise of MDMA use or ecstasy use in the nineties and the illicit market that had no quality control or safety built into it, pill testing was obviously a way to discern whether or not you had actual MDMA in the so-called ecstasy pill that you bought. And for me, it was just a kind of no-brainer thing to do. Because in British Columbia, at least at that time, there was fake pills circulating, PMMA, paramethoxy methamphetamine, and others, sometimes just methamphetamine, things that were either cut in or completely sold as replacements for. But the idea that Offering people a way to learn what they think they've got was just an obvious good thing to do. But I found myself on the wrong side of law enforcement's perspective on that. They threatened to shut us down regularly and got into media battles about And I didn't even know what the term harm reduction was at the time. But it was through that work that I got introduced to people who were doing HIV prevention and trying to open Vancouver's first supervised injection site back in the early two thousands. And that was sort of my pathway into the world of public health. Joe Moore (09:32): So were you involved with any of the American DanceSafe folks at that point? Kenneth Tupper (09:37): Yeah, we were kind of an affiliate. So Emmanuel Sverios, I think was leading things and sort of we're in touch sort of regularly, but in order that the cards, the information cards that were given out and sort of loosely followed the protocols and procedures that were set out by an American, the OG DanceSafe. But we were somewhat autonomous as well and obviously worked in our local ecosystem. Joe Moore (10:01): That's super interesting. Never really thought about that would have operated in the early days and then um this supervised injection site thing i find fascinating i think dr carl hart did a really good job in his books kind of popularizing the concept and somewhat normalizing the concept where i recall some of the swiss cases where people were able to maintain a habit for effectively many decades without any real health consequences and or their family noticing And that's because they had clean supplies. They were able to do that. Kenneth Tupper (10:40): Well, actually, the critique I have of supervised injection sites is they actually don't touch the supply side of things. Joe Moore (10:47): I think this one does, but I think in Canadian markets. But you might know better. Kenneth Tupper (10:53): Yeah, so as it was set up, the people who used it had to procure illicitly off-site on the street market and then come in and use under medical supervision. So they could get sterile syringes, have an overdose responded to, have other wound care. I mean, there's a fully sort of wraparound healthcare and social service connection built into the site, which was part of the argument for putting it in place, was giving people a point of access instead of puddle water in the back alley. They're using sterile syringes under nurses' supervision with lots of connections and a lot of effectiveness in terms of what it was set out to do. But in terms of still relying on the illicit supply, it didn't do as much as it could have done if they had offered people a pure pharmaceutical product of a known quantity, which is what was missing from that. But you're right, I think some of the European models provided heroin prescription or diacetylmorphine Joe Moore (11:49): Right. And I, you just kind of rattled my world puddle water. I never really kind of went that far, but I totally understand. It's probably factual. Kenneth Tupper (12:00): No, that's exactly what was happening. Joe Moore (12:02): My God. So yeah, this is, this is the not quite far part, far enough part that I think we all kind of want to address in psychedelia because it's, you know, it's complicated if you're, being sold what you think is LSD and you're buying something like two five I n bomb that can just harm you, kill you. And, you know, the experience might be fine the first ten times. But there's, yeah, there's just really difficult math and data behind this. Kenneth Tupper (12:35): Well, let me sort of jump on that tangent for a second. So one of the realizations that I came to over the last decade with the toxic drug crisis, the opioid overdose crisis, was the sort of failure, the blind spot in the history of public health to recognize one of the most important interventions that was advanced over the last two hundred years, which is really all modern public health has been going since the mid-nineteenth century. And you know, we can count on one hand the number of big top five global interventions, immunization and vaccinations, clean drinking water, hand washing. But another key one that we've forgotten is the passage of pure food and rugs legislation. So prior to the eighteen eighties to nineteen twenties, that was a period of a couple of decades where that form of legislation got put in place around you know developed world prior to that there was no quality control or consumer safety standards you took your life in your hands when you bought a sandwich on the street or a drink at the bar and there was a public health sort of progressivist movement at that time to ensure that people who are selling things foods beverages and patent medicines that was before a pharmaceutical industry got sort of standardized were selling what they said they were selling. And prior to that, there was a lot of risk involved in just taking, buying anything...
/episode/index/show/psychedelicstoday/id/43208488
info_outline
PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study
08/12/2026
PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study
This is an important discussion about harms, and what we should be doing about them. Josh and Roman are working on a major study at Emory University to answer some of the basic and outstanding questions we have about psychedelic risks and cases that can be challenging to recover from. We have a lot of work to do characterizing these experiences, and developing appropriate treatments for helping people bounce back more quickly.
/episode/index/show/psychedelicstoday/id/42413920
info_outline
PT 659 - Megan Bowers & Mikayla Hellwich
08/05/2026
PT 659 - Megan Bowers & Mikayla Hellwich
This is a special episode featuring two of our favorite organizations. DanceSafe and Shulgin Foundation. Listen to Joe Moore record with the heads of these orgs and learn about how you may be able to buy some art to support them. This is a singularly important history and partnership.
/episode/index/show/psychedelicstoday/id/42332095
info_outline
PT 658 - Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics
07/31/2026
PT 658 - Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics
My friend Mareesa joins us again on PT to discuss art, integration, psychedelic experiences without drugs, the heros journey and her smaller sphinxes that may start touring the country! Enjoy! Here are some machine generated shownotes if you find them useful! Show Notes Sphinx Gate began as a pair of monumental 34-foot sculptures at Burning Man. Now, Mareesa Stertz and her collaborators are developing smaller, portable versions that could bring the experience to festivals, conferences, and communities around the country. The installation is designed as a sober rite of passage—one that draws on psychedelic experience without requiring anyone to take a drug. Participants move through four portals centered on the mind, body, heart, and destiny. Along the way, they are invited to identify a recurring personal story, notice how it lives in the body, meet it with greater compassion, and consider what might exist beyond it. Mareesa and Joe explore how the project draws from the Hero’s Journey, Carl Jung’s concept of individuation, participatory art, ritual, somatic awareness, and the riddles traditionally associated with the sphinx. They also discuss the importance of community in psychedelic integration, the stories and inherited beliefs that disrupt self-trust, and why healing is rarely the result of one dramatic experience. The conversation expands into peer support, the Global Psychedelic Society, the risks of presenting psychedelics as a quick fix, and the challenge of remaining fully human as artificial intelligence becomes more embedded in everyday life.
/episode/index/show/psychedelicstoday/id/42281285
info_outline
PT 657 - Rachel Turetzky PhD & Douglas S. Wingate DTCM: The Eight-Circuit Model, Metaprogramming, and Psychedelic Therapy
07/23/2026
PT 657 - Rachel Turetzky PhD & Douglas S. Wingate DTCM: The Eight-Circuit Model, Metaprogramming, and Psychedelic Therapy
Kyle and Joe interview Rachel Turetzky & Douglas S. Wingate about their perspectives on the Wilson\Leary 8 Circuit Model of consciousness. They recently released a CE approved program on to train therapists on this model and how to integrate the into your clinical therapy practice. In this episode: Maybe Day and maybe logic: Honoring Robert Anton Wilson and learning to hold beliefs, models, and interpretations more lightly Reality tunnels: How biology, experience, culture, and conditioning filter our perception of reality Robert Anton Wilson’s legacy: Guerrilla ontology, stand-up philosophy, Prometheus Rising, and using humor to destabilize rigid beliefs Timothy Leary beyond the caricature: His early work in psychology, the development of the Eight-Circuit Model, and the parts of his intellectual legacy that are often overlooked The first four circuits: Bodily safety, emotional territory, language and symbolic thinking, and social and relational conditioning The upper circuits: Sensory and somatic intelligence, metacognition, archetypal and transpersonal experience, and unitive states of consciousness Metaprogramming: Identifying the beliefs, imprints, and automatic patterns shaping our lives—and developing the capacity to revise them Circuit Zero and Stanislav Grof: Prenatal and perinatal experience, the basic perinatal matrices, and the lasting influence of early development Normalizing unusual experiences: Archetypal encounters, ancestral material, entities, out-of-body experiences, synchronicities, and other phenomena that conventional psychology may struggle to interpret Psychedelics and re-imprinting: How expanded states may loosen entrenched developmental patterns and create opportunities for psychological change Pleasure as therapeutic material: Anhedonia, chronic survival states, the “hedonic intelligence” of Circuit Five, and learning to experience joy without treating it as a distraction from the work Clinical applications: Using the model during psychedelic preparation to identify intentions, developmental imprints, and material that may emerge Medicine and dosage selection: How MDMA, ketamine, psilocybin, LSD, and 5-MeO-DMT may produce different experiences depending on the intention and dose Integration and verticality: Grounding expansive, archetypal, or unitive experiences through the body, emotions, relationships, and everyday life Chapel Perilous: Understanding destabilizing experiences, ontological shock, spiritual emergencies, and the process of reconstructing meaning afterward Beyond psychedelics: Connections with yoga, meditation, occult practice, Chinese medicine, chakra systems, and other psychospiritual traditions The new course: The structure of The Eight-Circuit Model of Consciousness: An Integrative Framework for Psychedelic-Assisted Therapy, including its 14 lessons, practical exercises, assessments, certification, and continuing-education options
/episode/index/show/psychedelicstoday/id/42197075
info_outline
PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture
05/11/2026
PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture
Denver mushroom decriminalization changed the national conversation around psilocybin access, personal use, and grassroots psychedelic reform. In this episode of Psychedelics Today, Joe Moore speaks with Travis Tyler Fluck, an autognostic mycologist, educator, activist, end-of-life doula, and longtime Colorado mushroom community organizer. Fluck was involved in Denver’s 2019 psilocybin campaign, which made adult personal use and possession of psilocybin mushrooms the city’s lowest law enforcement priority. The campaign passed by a narrow margin and helped open the door for later reforms in Oakland, Washington, D.C., Oregon, Colorado, and beyond. This conversation looks at the people, ethics, and tensions behind Denver mushroom decriminalization. It also explores what happens after a law changes: how communities educate themselves, how personal use spaces develop, and how grassroots access fits alongside regulated psychedelic services.
/episode/index/show/psychedelicstoday/id/41257405
info_outline
PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium
05/08/2026
PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium
Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Center and Tasia Poinsatte of Healing Advocacy Fund. They join Joe Moore to discuss this year’s symposium, how it fits into Colorado’s evolving natural medicine landscape, and why Aspen has become a strong setting for serious public conversations about psychedelics. Hammel explains that the symposium is now in its third year and is designed to bring major psychedelic voices to Colorado’s West Slope. She also outlines the local roots of the Aspen Psychedelic Resource Center, which grew out of education and outreach work around decriminalization and the Natural Medicine Health Act. Poinsatte describes Healing Advocacy Fund’s broader role across Oregon, Colorado, and New Mexico, where the group works on safe access, implementation, affordability, and public education.
/episode/index/show/psychedelicstoday/id/40995465
info_outline
PT 654 - Erica Rex - Seeing What Is There
04/23/2026
PT 654 - Erica Rex - Seeing What Is There
Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore to discuss her book Seeing What Is There: My Search for Sanity in the Psychedelic Era. Rex brings an unusual mix of personal experience and scientific rigor. She came to psychedelic medicine after breast cancer, participation in Roland Griffiths’ clinical trial for cancer-related depression, and a long career in journalism covering science, nature, climate, and technology.
/episode/index/show/psychedelicstoday/id/40992160
info_outline
PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy
04/16/2026
PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy
ALS and ketamine therapy are at the center of this conversation with psychiatrist and , who was diagnosed with in late 2023. Alpert is a Boston-area psychiatrist with experience in MDMA-assisted therapy research for PTSD and a private practice that includes . Alberding shares what it has been like to face a fatal neurodegenerative illness while working with ketamine in a structured clinical setting. Alberding explains that he was not looking for a casual psychedelic experience. He wanted help facing fear, grief, loss of function, and the reality of death. Over time, ketamine-assisted psychotherapy became a tool for processing those changes more directly than talk therapy alone had allowed.
/episode/index/show/psychedelicstoday/id/40902760
info_outline
PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow
03/25/2026
PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow
Dr. Esme Dark joins Kyle Buller for a conversation on psychedelic therapy, somatic psychotherapy, and shadow work. Based in Australia, Dark is a clinical psychologist, somatic psychotherapist, and psychedelic therapist. She shares her perspective on Australia’s authorized prescriber model, the role of psychotherapy in psychedelic care, and what it means to work with the body before, during, and after a psychedelic experience. The discussion stays practical. Dark draws on her work in research settings, including psilocybin-assisted psychotherapy for generalized anxiety disorder at Monash University. She explains that Australia has not decriminalized psychedelics. Instead, psilocybin and MDMA can be prescribed in limited cases through a psychiatrist-led system. That distinction matters, especially as public discussion often moves faster than the actual clinical infrastructure. Kyle and Dark also explore what happens in the therapy room. They talk about nervous system activation, body-based awareness, co-therapy, breathwork, and the challenge of knowing when to intervene and when to stay out of the way. The episode also turns toward creativity, self-expression, and the parts of the self that often remain split off or underdeveloped.
/episode/index/show/psychedelicstoday/id/40621355
info_outline
PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics
03/19/2026
PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics
MAPS co-executive directors Betty Aldworth and Ismail Ali join Psychedelics Today to talk about leading one of the most visible organizations in the psychedelic field during a period of transition. The conversation covers their move into permanent leadership, how they work together, and how MAPS is thinking about research, education, policy, and movement strategy after a difficult period for the organization and the broader field.
/episode/index/show/psychedelicstoday/id/40548770
info_outline
PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape
03/09/2026
PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape
Jen Davenport joins Psychedelics Today to interview co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to engage with psychedelic ideas. Davenport is the founder of Iron Thread Partners and a graduate of the Vital psychedelic training program. Her work focuses on executive leadership, decision making, and organizational development. In this conversation she asks Moore about the evolution of Psychedelics Today and the changes he has witnessed across the psychedelic field over the past decade. Moore explains that Psychedelics Today began as a podcast exploring psychedelic research, therapy, and culture. Over time the project expanded into a media and education platform covering psychedelic science, harm reduction, and professional training. The organization now produces podcasts, journalism, courses, and public conversations about psychedelics and their place in modern society. A central part of the discussion is psychedelic integration. Moore notes that insight during a psychedelic experience does not automatically lead to lasting change. The integration process often requires continued work through journaling, meditation, therapy, and community support. These practices help people translate insights into stable changes in behavior and perspective. The conversation also explores policy changes in the United States. Colorado’s Natural Medicine framework is creating a regulated system for psychedelic services while the state also maintains a broader decriminalization approach. Moore discusses the tension between regulated access and grassroots psychedelic culture, as well as the questions around accessibility, pricing, and corporate participation. Davenport asks how executives and professionals are approaching psychedelics. In some circles psychedelics are framed as tools for creativity or performance. Moore cautions against this framing. Psychedelics often open difficult personal material and should be approached with care rather than treated as productivity tools. Education remains a recurring theme throughout the episode. As public interest grows, Moore stresses the importance of studying the legal landscape, understanding the scientific literature, and developing responsible practices for preparation and integration. The conversation offers a grounded look at how Psychedelics Today approaches the psychedelic resurgence. Rather than focusing on hype, Moore emphasizes education, safety, and thoughtful engagement with psychedelic experiences.
/episode/index/show/psychedelicstoday/id/40367020
info_outline
PT 649 - Melissa Lavasani and Jay Kopelman
02/19/2026
PT 649 - Melissa Lavasani and Jay Kopelman
& join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads , a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of , which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, . The conversation centers on veterans, the , and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC’s work on , including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know,...
/episode/index/show/psychedelicstoday/id/40167705
info_outline
PT 648 - Enamory - Couples Therapy with Ketamine
02/10/2026
PT 648 - Enamory - Couples Therapy with Ketamine
Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Kian and Kayla Knopp discuss their work integrating ketamine assisted psychotherapy with evidence based couples therapy models. Both guests trained as academic researchers at the University of California San Diego Veterans Affairs system, where they worked on large scale couples based PTSD trials. They later co founded Enamory to continue clinical work, train therapists, and conduct research focused specifically on relationships. Early Themes in Enamory and Couples Therapy The conversation begins with Dr. Kian and Dr. Knopp describing their background in couples based PTSD research and how that work shaped their clinical approach. They explain how existing couples therapy models often stall when partners cannot soften, access vulnerability, or understand each other’s internal experience. Their early exposure to MDMA assisted therapy research highlighted how psychedelic states can temporarily reduce defensiveness and rigid narratives.
/episode/index/show/psychedelicstoday/id/40066590
info_outline
PT 647 - Joshua White: Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support
01/22/2026
PT 647 - Joshua White: Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support
is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psychedelics Today about why real-time support matters, what it takes to run a national hotline, and what Fireside learned after more than 30,000 conversations since launch. White shares how his background as a lawyer and his early hotline volunteering shaped Fireside’s model. He also describes how festival harm reduction work, including lessons from Zendo-style support spaces, revealed a major gap: people often need help during an experience and after it ends. A major focus of the conversation is , Fireside’s new voice-to-voice role-play simulator designed to improve psychedelic support skills through low-stakes practice. Early Themes With Fireside Project Joshua White introduces Fireside Project as an accessible safety net for people who are actively having psychedelic experiences or processing past ones. The support line launched on April 14, 2021, and relies on trained community volunteers who commit to a year of service. White explains why anonymity matters. He argues that a phone-based container can make it easier for callers to share vulnerable material without fear of judgment. He also frames service as a key part of integration for volunteers who want to give back or prepare for work in the psychedelic field. Core Insights From Fireside Project White describes the early difficulty of building Fireside from scratch, including legal design, insurance hurdles, training development, and fundraising. He credits seed support from David Bronner and Dr. Bronner’s for helping Fireside prove that people would actually use a psychedelic support line. He also explains a key harm reduction point: calling emergency services during a non-medical psychedelic crisis can escalate risk. Fireside aims to help people regulate, re-orient, and stay safer when panic or fear shows up. Key concepts discussed include: The thin line between healing and traumatizing during high-intensity psychedelic states Why callers often need connection, not rescue How volunteer capacity and call volume shape how long conversations run The difference between support during an experience and longer-term coaching support Later Discussion and Takeaways With Fireside Project The conversation then turns to Lucy, a training tool White describes as a “flight simulator” for psychedelic practitioners. Lucy is not part of the live support line. Instead, it offers emotionally responsive role-play scenarios so trainees can practice staying grounded, tracking consent and boundaries, and responding to crisis cues. White also addresses recording and consent. He argues Fireside needs strong training feedback loops to improve safety and quality. He describes an anonymization approach designed to remove phone numbers, strip identifying details, and distort voices while preserving emotional tone. He also explains the post-call option for callers to delete their recorded conversation. Practical takeaways include: Simulation can help trainees stay regulated when intense material emerges Better training can reduce unnecessary diversion to emergency rooms Clear consent language and easy deletion workflows matter for trust Coaching can expand the continuum of psychedelic support beyond therapy
/episode/index/show/psychedelicstoday/id/39826185
info_outline
PT 646 - Manvir Singh: Shamanism the Timeless Religion
01/06/2026
PT 646 - Manvir Singh: Shamanism the Timeless Religion
Manvir Singh joins Psychedelics Today to unpack what shamanism means and why the term matters now. Singh is an anthropologist and author of Shamanism: The Timeless Religion. He argues that shamanism is not limited to “remote” societies or the past. Instead, it reliably reappears because it helps humans manage uncertainty, illness, and the unknown. This episode is relevant for the psychedelic community because “shaman” often gets used loosely, or avoided entirely. Singh offers a clear framework for talking about shamanic practice without leaning on romantic myths, drug-centered assumptions, or rigid definitions that do not fit the cross-cultural record. Early Themes With Manvir Singh Early in the conversation, Manvir Singh explains why many classic definitions of shamanism break down when tested across cultures, including in Siberia where the term originated. He discusses how popular images of shamanism often center “soul flight” and fixed cosmologies. However, ethnography shows more variation, including possession, spirit proximity, and different ways practitioners describe altered experience. Singh also traces his path into anthropology, including long-term fieldwork with the Mentawai people off the west coast of Sumatra. There, he studied ritual specialists known as kerei and saw how central they are to healing, ceremony, and community life. Core Insights From Manvir Singh At the center of the episode, Manvir Singh offers a practical three-part definition. He emphasizes these shared traits as the “beating heart” of shamanism across many settings: A non-ordinary state (trance, ecstasy, or another altered mode) Engagement with unseen beings or realities (spirits, gods, ancestors, witches, ghosts) Services such as healing and divination Singh also explores taboo, restriction, and “otherness.” He explains how shamans often cultivate social and psychological distance through initiations, deprivation, and visible markers. This helps communities experience the practitioner as different in kind, which increases credibility when the practitioner claims access to hidden forces. Later Discussion and Takeaways With Manvir Singh Later, Manvir Singh challenges common psychedelic narratives that treat psychedelics as the universal engine of religion or shamanism. He notes that many shamanic traditions do not rely on psychedelics at all, and that rhythmic music, drumming, dance, and social ritual can reliably produce trance states. He also clarifies a key mismatch in many contemporary “ayahuasca tourism” settings: in many traditional contexts, the specialist takes the substance to work on behalf of the patient, rather than turning the participant into the primary visionary practitioner. Practical takeaways for the psychedelic field include: Use definitions that fit cross-cultural evidence, not marketing language. Avoid assuming psychedelics are required for mystical experience. Notice how authority gets built through ritual, training, and otherness, not only through pharmacology.
/episode/index/show/psychedelicstoday/id/39632635
info_outline
PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking
12/28/2025
PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking
(Brighton, UK) joins Joe Moore for a grounded conversation on the boom in functional mushrooms and why the category may be moving too quickly. As the founder of , Oli works with consumers and brands to demystify functional mushrooms, with a focus on education, traceability, and realistic expectations. The conversation begins with a critique of wellness hype cycles. Oli explains how consumer desperation for help with anxiety, sleep, stress, and cognition can create an opening for a rapid wave of products that are not always grounded in careful sourcing or clear science. Using as a case study, he contrasts popular cognitive claims with traditional use, arguing that the most useful path forward is to slow down, get more literate about mechanisms, and build a market that can sustain trust over time. Systems and Culture Oli describes how individual health is inseparable from community realities, including food access, class dynamics, and what wellness advice can sound like when it lands from a place of privilege. They discuss mycelial thinking as a practical framework for collaboration and resource-sharing, and why mushrooms tend to attract unusually generous “teach everyone” communities. They also explore the role of mushrooms in meaning-making and consciousness. Oli shares personal reflections on mushrooms as allies, the felt sense of “agency” in psychedelic experiences, and how those experiences can encourage behavioral change without forcing it. The conversation touches on alcohol culture in the UK and the possibility of non-alcoholic alternatives, including how , , and other botanicals can support social confidence and energy for some people. Finally, they look ahead at fungal innovation beyond supplements: materials, soil health, regenerative approaches, bioremediation, and what the broader psychedelic movement might learn from fungi’s patience, symbiosis, and balance. Key themes and takeaways 1) Why functional mushrooms feel “too fast” right now Oli argues that functional mushrooms have accelerated into a high-pressure wellness marketplace, with brands rushing products to market and consumers struggling to determine what is legitimate, traceable, and effective. He draws parallels to the UK CBD market, describing how oversaturation and inconsistent quality can erode trust and collapse prices. 2) Lion’s mane, tradition, and mechanism Lion’s mane is a useful example of how modern marketing can outrun nuance. Oli notes the gap between popular cognitive claims and traditional use, and points toward the gut-brain axis as one plausible bridge that requires more careful explanation and patience. 3) “Functional mushrooms” as a frame Oli prefers the term functional mushrooms over medicinal mushrooms, emphasizing systems-level support rather than a pharmaceutical model. He describes a view of health that starts on the cellular level and asks what supports function, resilience, and prevention. 4) Health is individual and collective Oli speaks candidly about barriers to wellness in the UK, including food poverty, access to education about cooking, and how class dynamics shape what health messaging sounds like. The broader point is structural: it is difficult to talk about supplements without considering the baseline conditions of daily life. 5) Mycelial thinking, futures work, and collaboration The conversation highlights “mycelial thinking” as more than a metaphor. Oli describes collaborations in futures-oriented communities and how fungal logic can inform collaboration, non-zero-sum outcomes, and resource sharing. 6) Mushroom culture and the instinct to share Joe notes how strikingly generous mushroom communities can be, especially around cultivation and identification. Oli agrees and adds a provocative angle: the possibility of “agency” in fungi and a sense that mushrooms invite humans into relationship, curiosity, and participation. 7) Alcohol culture and alternatives Oli reflects on nearly three years without alcohol and describes how functional mushrooms and other botanicals can support mood, energy, and social confidence for some people. They also discuss the realities of events culture, including the need for more inclusive non-alcoholic options and sensitivity to addiction histories. 8) The next 10 years of fungi They look at the expansion of fungi into materials, fashion, regenerative agriculture, soil health, and bioremediation. Oli emphasizes balance: fungal innovations are promising, but scaling and real-world constraints matter. 9) What the psychedelic movement can learn from fungi Oli critiques extractive, capital-driven dynamics in the psychedelic ecosystem and suggests fungi offer a different ethic: patience, humility, symbiosis, and realism about parasitism and imbalance.
/episode/index/show/psychedelicstoday/id/39548295
info_outline
PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation
12/22/2025
PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation
In this live episode, joins to discuss . She explains why many Indigenous initiatory systems begin with consultation and careful assessment of the person, often using divination and lineage-based diagnostic methods before anyone enters ceremony. Eastman contrasts that with modern frameworks that can move fast, rely on short trainings, or treat the medicine as a stand-alone intervention. Early Themes: Ritual, Preparation, and the Loss of Container Eastman describes her background, including ancestral roots in Mexico and her later work at Crossroads Ibogaine in Mexico, where she supported early ibogaine work with veterans. She frames her broader work as cultural bridging that seeks respect rather than fetishization, and assimilation into modern context rather than appropriation. Early discussion focuses on: Why initiatory traditions emphasize purification, preparation, and long timelines Why consultation matters before any high-intensity medicine work How decades of training shaped traditional initiation roles Why people can get harmed when they treat medicine as plug and play Core Insights: Alchemy, Shadow, and Doing the Work A major throughline is Eastman’s critique of the belief that a psychedelic alone will erase trauma. She argues that shadow work remains part of the human condition, and that healing is less about a one-time fix and more about building capacity for relationship with the unconscious. Using alchemical language, she describes “nigredo” as fuel for the creative process, not as something to eliminate forever. Key insights include: Psychedelics are tools, not saviors You cannot outsource responsibility to a pill, a modality, or a facilitator Progress requires practice, discipline, and honest engagement with what arises “Healing” often shows up as obstacles encountered while trying to live and create Later Discussion and Takeaways: Iboga, Ethics, and Biocultural Stewardship Joe and Tricia move into a practical and ethically complex discussion about iboga supply chains, demand pressure, and the risks of amplifying interest without matching it with harm reduction and reciprocity. Eastman emphasizes medical screening, responsible messaging, and supporting Indigenous-led stewardship efforts. She also warns that harm can come from both under-trained modern facilitators and irresponsible people claiming traditional legitimacy. Concrete takeaways include: Treat iboga and ibogaine as high-responsibility work that demands safety protocols Avoid casual marketing that encourages risky self-administration Support Indigenous-led biocultural stewardship and reciprocity efforts Give lineage carriers a meaningful seat at the table in modern policy and clinical conversations Frequently Asked Questions Who is Tricia Eastman? Tricia Eastman is an author, facilitator, and founder of . Her work focuses on cultural bridging, initiation frameworks, and Indigenous-led stewardship. What is Seeding Consciousness about? The book examines plant medicine through initiatory traditions, emphasizing consultation, ritual, preparation, and integration rather than reductionistic models. Why does Tricia Eastman critique modern psychedelic models? She argues that many models remove the ritual container and long-form preparation that reduce risk and support deeper integration. Is iboga or ibogaine safe? With the right oversite, yes. Eastman stresses that safety depends on cardiac screening, careful protocols, and experienced oversight. She warns against informal or self-guided use. How can people support reciprocity and stewardship? She encourages donating or supporting Indigenous-led biocultural stewardship initiatives like and aligning public messaging with harm reduction. Closing Thoughts This episode makes a clear case that Tricia Eastman Seeding Consciousness is not only a book about psychedelics, but a critique of how the field is developing. Eastman argues that a successful future depends on mature containers, serious safety culture, and respectful partnership with lineage carriers, especially as interest in iboga and ibogaine accelerates. Links Transcript Joe Moore Hello, everybody. Welcome back. Joe Moore with you again from Psychedelics Today, joined today by Tricia Eastman. Tricia, you just wrote a book called Seeding Consciousness. We're going to get into that a bunch today, but how are you today? [00:00:16.07] - Tricia Eastman I'm so good. It's exciting to be live. A lot of the podcasts I do are offline, and so it's like we're being witnessed and feels like just can feel the energy behind It's great. [00:00:31.11] - Joe Moore It's fun. It's a totally different energy than maybe this will come out in four months. This is real, and there's people all over the world watching in real-time. And we'll get some comments. So folks, if you're listening, please leave us some comments. And we'd love to chat a little bit later about those. [00:00:49.23] - Tricia Eastman I'm going to join the chat so that I can see... Wait, I just want to make sure I'm able to see the comments, too. Do I hit join the chat? [00:01:01.17] - Joe Moore Sometimes you can, sometimes you can't. I can throw comments on the screen so we can see them together. [00:01:07.02] - Tricia Eastman Cool. [00:01:08.03] - Joe Moore Yeah. So it'll be fun. Give us comments, people. Please, please, please, please. Yeah, you're all good. So Tricia, I want to chat about your book. Tell us high level about your book, and then we're going to start digging into you. [00:01:22.10] - Tricia Eastman So Seeding Consciousness is the title, and I know it's a long subtitled Plant Medicine, Ancestral Wisdom, Psychedelic Initiation. And I felt like it was absolutely necessary for the times that we are in right now. When I was in Gabon in 2018, in one of my many initiations, as as an initiative, the Fung lineage of Buiti, which I've been practicing in for 11 years now, I was given the instructions. I was given the integration homework to write this book. And I would say I don't see that as this divine thing, like you were given the assignment. I think I was given the assignment because it's hard as F to write a book. I mean, it really tests you on so many levels. I mean, even just thinking about putting yourself out there from a legal perspective, and then also, does it make any sense? Will anyone buy it? And on Honestly, it's not me. It's really what I was given to write, but it's based on my experience working with several thousand people over the years. And really, the essence of it is that in our society, we've taken this reductionistic approach in psychedelics, where we've really taken out the ritual. [00:02:54.05] - Tricia Eastman Even now with the FDA trial for MDMA for PTSD. There's even conversations with a lot of companies that are moving forward, psychedelics, through the FDA process, through that pathway, that are talking about taking the therapy out. And the reality is that in these ancient initiatic traditions, they were very long, drawn out experiences with massive purification rituals, massive amounts of different types of practice in order to prepare oneself to meet the medicine. Different plants were taken, like vomatifs and different types of purification rituals were performed. And then you would go into this profound initiatic experience because the people that were working with you that were in, we call it the Nema, who gives initiations, had decades of training and experience doing these types of initiatic experiences. So if you compare that to the modern day framework, we have people that go online and get a certificate and start serving people medicine or do it in a context where maybe there isn't even an established container or facilitator whatsoever. And so really, the idea is, how can we take the essence of this ancient wisdom wisdom, like when you look at initiation, the first step is consultation, which is really going deep into the history of the individual using different types of techniques that are Indigenous technologies, such as different forms of divination, such as cowrie shell readings. [00:04:52.18] - Tricia Eastman And there's different types of specific divinations that are done in different branches of And before one individual would even go into any initiation, you need to understand the person and where they're coming from. So it's really about that breakdown of all of that, and how can we integrate elements of that into a more modern framework. [00:05:24.23] - Joe Moore Brilliant. All right. Well, thank you for that. And let's chat about you. You've got a really interesting past, very dynamic, could even call it multicultural. And you've got a lot of experience that informed this book. So how did this stuff come forward for you? [00:05:50.02] - Tricia Eastman I mean, I've never been the person to seek anything. My family on my mother's side is from Mexico, from Oaxaca, Trique, Mixtec, and Michica. And we had a long lineage of practice going back to my, at least I know from my great, great grandmother, practicing a blend of mestiza, shamanism, combining centerea and Catholicism together. So it's more of like a syncratic mestiza, mestiza being mixed tradition. And so I found it really interesting because later on, when my grandfather came to the United States, he ended up joining the military. And in being in the US, he didn't really have a place. He's very devout spiritual man, but he didn't have a place to practice this blended spiritual tradition. So the mystical aspect of it went behind. And as I started reconnecting to my ancestral lineage, this came forth that I was really starting to understand the mystical aspect of my ancestry. And interestingly, at the same time, was asked to work at Crossroads Abigain in Mexico. And it's so interesting to see that Mexico has been this melting pot and has been the place where Abigain has chosen to plant its roots, so to say, and has treated thousands of veterans. [00:07:36.28] - Tricia Eastman I got to be part of the group of facilitators back over 10 years ago. We treated the first Navy Seals with Abogaine, and that's really spurred a major interest in Abogaine. Now it's in every headline. I also got 10 I got initiated into the Fung lineage of Buiti and have really studied the traditional knowledge. I created a nonprofit back in 2019 called Ancestral Heart, which is really focused on Indigenous-led stewardship. Really, the book helps as a culmination of the decade of real-world experience of combining My husband, Dr. Joseph Barzulia. He's a psychologist. He's also a pretty well-known published researcher in Abigain and 5MEO-DMT, but also deeply spiritual and deeply in respect for the Indigenous traditions that have carried these medicines before us. So we've really been walking this complex path of world bridging between how we establish these relationships and how we bring some of these ancient knowledge systems back into the forefront, but not in a way of fetishizing them, but in a way of deeply respecting them and what we can learn, but from our own assimilation and context versus appropriation. So really, I think the body of my work is around that cultural bridging. [00:09:31.07] - Joe Moore That's brilliant. And yeah, there's some really fun stuff I learned in the book so far that I want to get into later. But next question is, who is your intended audience here? Because this is an interesting book that could hit a few categories, but I'm curious to hear from you. [00:09:49.02] - Tricia Eastman It's so funny because when I wrote the book, I wasn't thinking, oh, what's my marketing plan? What's my pitch? Who's my intended audience? Because it was my homework, and I knew I needed to write the book, and maybe that was problematic in the sense that I had to go to publishers and have a proposal. And then I had to create a formula in hindsight. And I would say the demographic of the book mirrors the demographic of where people are in the psychedelic space, which It's skewed slightly more male, although very female. I think sex isn't necessarily important when we're thinking about the level of trauma and the level of spiritual healing and this huge deficit that we have in mental health, which is really around our disconnection from our true selves, from our heart, from our souls, from this idea of of what Indigenous knowledge systems call us the sacred. It's really more of an attitude of care and presence. I'm sure we could give it a different name so that individuals don't necessarily have any guard up because we have so much negative conditioning related to the American history of religion, which a lot of people have rejected, and some have gone back to. [00:11:37.06] - Tricia Eastman But I think we need to separate it outside of that. I would say the demographic is really this group of I would say anywhere from 30 to 55 male females that are really in this space where maybe they're doing some of the wellness stuff. They're starting to figure some things out, but it's just not getting them there. And when something happens in life, for example, COVID-19 would be a really great example. It knocks them off course, and they just don't have the tools to find that connection. And I would say it even spans across people that do a lot of spiritual practice and maybe are interested in what psychedelics can do in addition to those practices. Because when we look at my view on psychedelics, is they fit within a whole spectrum of wellness and self-care and any lineage of spiritual practice, whether it's yoga or Sufism or Daoist tradition. But they aren't necessarily the thing that... I think there's an over focus on the actual substance itself and putting it on a pedestal that I think is problematic in our society because it goes back to our religious context in the West is primarily exoteric, meaning that we're seeking something outside of ourselves to fulfill ourselves. [00:13:30.29] - Tricia Eastman And so I think that when we look at psychedelic medicines as this exoteric thing versus when we look at initiatory traditions are about inward and direct experience. And all of these spiritual practices and all of these modalities are really designed to pull you back into yourself, into having a direct relationship with yourself and direct experience. And I feel like the minute that you are able to forge that connection, which takes practice and takes discipline, then you don't need to necessarily look at all these other tools outside of yourself. It's like one of my favorite analogies is the staff on the Titanic were moving the furniture around as it was sinking, thinking that they might save the boat from sinking by moving the furniture around. I think that's how we've been with a lot of ego-driven modalities that aren't actually going into the full unconscious, which is where we need to go to have these direct experiences. Sorry for the long answer, but it is for everybody, and it's not just about psychedelics. Anyone can take something from this doing any spiritual work. But we talk a lot about the Indigenous philosophy and how that ties in alongside with spiritual practice and more of this inner way of connecting with oneself and doing the work. [00:15:21.22] - Tricia Eastman And I think also really not sugar coating it in the sense that the psychedelics aren't going to save us. They're not going to cure PTSD. Nothing you take will. It's you that does the work. And if you don't do the work, you're not going to have an 87 % success rate with opioid use disorder or whatever it is, 60 something % for treatment-resistant depression or whatever. It's like you have to do the work. And so we can't keep putting the power in the modality reality or the pill. [00:16:03.18] - Joe Moore Yeah, that makes sense. So you did an interesting thing here with this book, and it was really highlighting aspects of the alchemical process. And people don't necessarily have exposure. They hear the words alchemy. I get my shoulders go up when I hear alchemizing, like transmutation. But it's a thing. And how do we then start communicating this from Jung? I found out an interesting thing recently as an ongoing student. Carl Jung didn't necessarily have access to all that many manuscripts. There's so many alchemical manuscripts available now compared to what he had. And as a result, our understanding of alchemy has really evolved. Western alchemy, European alchemy, everybody. Perhaps Kmetic, too. I don't know. You could speak to that more. I don't keep track of what's revealed in Egypt. So it's really interesting to present that in a forward way? How has it been received so far? Or were you nervous to present this in this way? [00:17:25.10] - Tricia Eastman I mean, honestly, I think the most important The important thing is that in working with several thousand people over the years, people think that taking the psychedelic and the trauma is going to go away. It's always there. I mean, we We archetypically will have the shadow as long as we need the shadow to learn. And so even if we go into a journey and we transcend it, it's still there. So I would say that the The feedback has been really incredible. I mean, the people that are reading... I mean, I think because I'm weaving so many different, complex and deep concepts into one book, it might be a little harder to market. And I think the biggest bummer was that I was really trying to be respectful to my elders and not say anything in the title about Iboga and Abigain, even though I talk a lot about it in the book, and it's such a hot topic, it's really starting to take off. But the people that have read it really consider it. They really do the work. They do the practices in the book, and I'm just getting really profound feedback. So that's exciting to me because really, ultimately, alchemy... [00:18:55.22] - Tricia Eastman Yeah, you're right. It gets used Used a lot in marketing lingo and sitting in the depth of the tar pit. For me, when I was in Gabon, I remember times where I really had to look at things that were so dark in my family history that I didn't even realize were mine until later connected to my lineage. And the dark darkness connected to that and just feeling that and then knowing really the truth of our being is that we aren't those things. We're in this process of changing and being, and so nothing is is fixed, but there is a alchemical essence in just learning to be with it. And so not always can we just be with something. And and have it change, but there are many times that we can actually just be with those parts of ourselves and be accepting, where it's not like you have to have this intellectualized process It's just like, first you have the negrado, then you tune into the albeda, and you receive the insights, and you journal about it, and da, da, da, da, da Action, Mars aspect of it, the rubeda of the process. It's not like that at all. [00:20:44.15] - Tricia Eastman It's really that the wisdom that comes from it because you're essentially digesting black goo, which is metaphoric to the oil that we use to power all of society that's pulled deep out of the Earth, and it becomes gold. It becomes... And really, the way I like to think of it is like, in life, we are here to create, and we are not here to heal ourselves. So if you go to psychedelic medicine and you want to heal yourself, you're going to be in for... You're just going to be stuck and burnt out because that's not what we're here to do as human beings, and you'll never run out of things to heal. But if you You think of the negrado in alchemy as gasoline in your car. Every time you go back in, it's like refilling your gas tank. And whatever you go back in for as you're moving in the journey, it's almost like that bit of negrado is like a lump of coal that's burning in the gas tank. And that gets you to the...
/episode/index/show/psychedelicstoday/id/39494495
info_outline
PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy
12/02/2025
PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy
Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director of , the legislative director at , and a key strategist behind Texas’ landmark interest in ibogaine research. He also advises for . His work sits at the intersection of science, policy, and lived experience, and this conversation offers a clear look into what is happening right now. Early Themes: The Rise of State Advocacy Davidson explains how he entered politics at nineteen and how his professional path merged with psychedelic policy work during the 2021 Texas legislative session. Through that first bill, he saw how science, bipartisan cooperation, and strong local leadership could advance major reform. Early discussion focuses on: How Texas became the first state to pass a major psychedelic research bill Why ibogaine became a central focus How the special operations community helped shift political momentum The personal mental health stories that shaped Davidson’s commitment This section also highlights how entered the conversation through veterans, researchers, and state lawmakers who felt the urgency of the opioid crisis and traumatic brain injury. Core Insights: Ibogaine, Risk, and the New Research Model In the middle portion of the episode, Davidson breaks down the strategy, challenges, and promise behind ibogaine research and state-based policy innovation. Key insights include: The unique bipartisan environment in Texas Why stories from veterans and spouses moved lawmakers The importance of medical screening for cardiac risk Why research is essential for safety How states can use funding, revenue sharing, and public health goals to shape future access What policymakers are watching right now Effectiveness for opioid use disorder Data from traumatic brain injury studies Cardiac safety protocols The risk of untreated depression and addiction The national security implications of forcing service members to seek illegal care Davidson also explains why removing the psychedelic experience from the molecule remains controversial and why many researchers believe the full experience matters. Later Discussion and Takeaways: The Road Ahead for American Ibogaine In the final part of the conversation, Davidson speaks about the future of American Ibogaine and the broader psychedelic field. He outlines why local leadership matters, why federal funding, like what is supporting, could be the next major tipping point, and how big pharmaceutical companies may eventually enter the space through acquisitions or proprietary molecule development. Concrete takeaways include: States should expect clear benefits: lower-cost treatments, shared revenue, and local control Community leaders, not outsiders, often drive legislative wins The need for long-term safety data remains National security concerns highlight why regulated access must expand Federal research money could radically transform the pace and scale of studies He also encourages listeners to join or build local organizations, since nearly every major win comes from people who live in the state pushing from the ground up. Frequently Asked Questions Is Ibogaine safe? Ibogaine has cardiac risks that require medical screening and careful monitoring. Researchers stress that safety improves with proper protocols and more clinical data. Why is Ibogaine important for veterans? Many special operations veterans report major benefits for traumatic brain injury, PTSD, and addiction. Their stories have driven political momentum. How are states involved in Ibogaine research? States like Texas are funding clinical trials, drug development, shaping policy, and exploring revenue and access models to support long-term public health benefits. Will Ibogaine become federally supported in America? New federal interest, including major grants and bipartisan discussions, suggests that broader support may be coming in the next few years. Closing Thoughts This episode shows why the work of Logan Davidson sits at the center of today’s psychedelic resurgence. It highlights a complex but hopeful moment where science, policy, and lived experience are beginning to align. As American Ibogaine research expands, state leaders, clinicians, veterans, and advocates all have a role in shaping a safer and more effective future for these treatments.
/episode/index/show/psychedelicstoday/id/39213460
info_outline
PT 642 - Michael Sapiro PhD - Truth Medicine, Psychedelics, and Living Your Truth
11/28/2025
PT 642 - Michael Sapiro PhD - Truth Medicine, Psychedelics, and Living Your Truth
In this episode, joins Kyle Buller to explore truth, healing, and psychedelic-assisted psychotherapy through the lens of his new book, . A clinical psychologist, ordained Zen Buddhist monk, retreat leader, and fellow at the Institute of Noetic Sciences, he blends Buddhist psychology, trauma work, and consciousness studies. The discussion focuses on how people discover and live their truth, and why that truth becomes the core medicine in healing. Early in the Podcast with Michael Sapiro describes how years of clinical work and retreat facilitation shaped his understanding of healing. Real transformation happens when people speak truths they have never allowed themselves to say out loud. These truths often relate to childhood experiences, identity, and how people learned to stay safe. Key early themes include insight into: • Truth as a physical and emotional “ring” in the body • Personas formed in childhood to avoid rejection • Depression and anxiety caused by living from those personas The conversation explores how frightening it can be to challenge old roles and family narratives, yet how necessary it is for authentic healing. Core Insights from Michael Sapiro outlines his model of preparation, psychedelic sessions, and integration, especially in ketamine-assisted psychotherapy. Preparation often includes discovering what he calls the “heart of the hurt” and building trust for the internal process. Core insights include: • Tracing patterns back to their origins in early experience • Using guided imagery, breathwork, and somatic awareness to practice surrender • Understanding healing as applying love to wounded parts • Understanding growth as becoming who you would be without old limits Additional points: • Medicine sessions create real practice in letting go • Defenses should be engaged with, not fought • Sensations in the body offer essential guidance Later Discussion and Takeaways with Michael Sapiro Michael compares one-on-one psychotherapy with retreat work. In group settings he holds space and supports safety, while in individual sessions he uses a blend of silence and active therapeutic guidance. He also shares personal truth work, including embracing his own “bigness,” understanding ethics as part of spirituality, and learning to endure anxiety without falling into shame. Listeners gain practical guidance for nurturing wounded parts, developing the ability to endure challenging states, and allowing their strengths to emerge. Frequently Asked Questions Who is Michael Sapiro? Michael Sapiro is a clinical psychologist, ordained Zen Buddhist monk, psychedelic psychotherapist, retreat leader, and research fellow at the . What is the main idea of Truth Medicine by Michael Sapiro? teaches that discovering and living one’s personal truth is the core of healing, with psychedelics serving as a tool that helps reveal and embody that truth. How does Michael Sapiro use ketamine in therapy? He uses ketamine within a structured model involving preparation, supportive dosing sessions, and integration focused on compassion, endurance, and meaningful change. Does he only work in group settings? No. He leads retreats, but much of his work is individual psychedelic psychotherapy focused on trauma, personal truth, and growth. What can clinicians learn from his approach? Clinicians can learn how to balance guided intervention with open space, work directly with defenses, and support healing as both love and action. Closing Thoughts This conversation with offers a grounded, practical view of how truth, compassion, and psychedelic-assisted psychotherapy can support real change in the current psychedelic resurgence. By blending body awareness, ethical clarity, and personal growth, this episode provides useful guidance for therapists, guides, and seekers who want to bring more truth medicine into their lives and communities.
/episode/index/show/psychedelicstoday/id/39191385
info_outline
PT 641 - Joe Moore & Kyle Buller - Holotropic Breathwork, Somatics, and Foundations for Psychedelic Work
11/26/2025
PT 641 - Joe Moore & Kyle Buller - Holotropic Breathwork, Somatics, and Foundations for Psychedelic Work
sits at the center of this wide ranging conversation between Psychedelics Today co-founders Joe Moore and Kyle Buller. Drawing from decades of personal practice and assorted types of breathwork facilitation, they explore how breathwork methods from the Grof lineage including can prepare people for psychedelic work, support difficult journeys, and deepen integration over time. Kyle shares how his near death experience, somatic training, and breathwork facilitation shaped this new course on breathwork foundations, while Joe reflects on how reading Dr Stanislav Grof and years of experience in Holotropic Breathwork changed how he approaches psychedelics. Early Themes: Roots, Lineages, and First Encounters The episode opens with how each of them first found breathwork. Joe discovered Grof’s writing in college, then traveled to Dreamshadow workshops long before he worked seriously with psychedelics. Kyle came to style breathwork while studying transpersonal psychology at Burlington College, arriving as a skeptic who assumed people were exaggerating until his first session opened into a full psychedelic level process. They trace the roots of breathwork in modern psychology back to Wilhelm Reich, character armor, and early somatic approaches, then follow that thread into Grof’s work and later branches. Joe and Kyle map out the different schools that emerged, including Grof Transpersonal Training, Grof Legacy Training, and Dreamshadow, and explain why the term “breathwork” has become a huge umbrella that covers everything from Wim Hof to short online sessions that are not actually Holotropic Breathwork. Core Insights: Breath, Nervous System, and Working the Edges In the middle of the episode they move into what this new foundations course actually covers and why it matters now. Rather than promising quick fixes, Kyle frames breath as a flexible tool for: Preparation before psychedelic sessions Navigation during intense or destabilizing moments Integration and nervous system support afterward They discuss window of tolerance, fight flight freeze responses, and how fast, deep breathing can open powerful experiences but also risk overwhelm if there is no somatic literacy. Kyle shares a vivid story from a ketamine training where his near death trauma was reactivated and how simple breath awareness, slow belly breathing, and body based skills kept him from panicking or fleeing. Throughout, they return to a key point: Holotropic Breathwork and related practices can restore agency. The breather chooses when to intensify, when to slow down, and how far to go, which can be deeply reparative for people whose trauma involved a loss of control. Later Discussion and Takeaways: Holotropic Breathwork as Foundation, Not Shortcut Later in the conversation, Joe and Kyle caution against “keeping up with the Joneses” in psychedelic culture. They talk about people chasing ever bigger doses, accruing trauma, and then needing years of therapy to sort it out. Breathwork, including Holotropic Breathwork in a well held group setting, is offered as a slower, more grounded way to explore non ordinary states while building skills that transfer into medicine work. They outline the core components of Grof lineage breathwork: intensified breathing, evocative music, focused body support, expressive art, and group sharing in a safe container. Joe highlights how group process, mandala drawing, and simply being witnessed can be as healing as the inner journey itself. They also flag practical next steps: Kyle’s self paced breathwork at the , upcoming live online sessions, and in person weekend workshops in places like Breckenridge. Frequently Asked Questions What is Holotropic Breathwork? Holotropic Breathwork is a structured group process developed by Stan and Christina Grof that uses accelerated breathing, evocative music, supportive bodywork, art, and integration sharing to access non ordinary states of consciousness without substances. Is Holotropic Breathwork as intense as psychedelics? For some people, yes. Joe and Kyle both describe Holotropic Breathwork sessions that matched the depth of powerful LSD or ayahuasca journeys, while also noting that some sessions are quiet, restful, and focused on simple nervous system regulation. Can I do Holotropic Breathwork alone at home? They strongly suggest caution. Gentle breath practices can be explored solo, but Holotropic Breathwork as taught in the Grof lineages is designed for a trained facilitation team and a group container to reduce risk and support intense emotional or somatic processes. How does Holotropic Breathwork help with psychedelic preparation and integration? Breathwork helps people learn their own nervous system, practice staying with difficult material, and build trust in inner process. These skills often translate into more resilience, flexibility, and agency before, during, and after psychedelic sessions. Is Holotropic Breathwork backed by research? Research on breathwork is growing, especially around heart rate variability, stress, and subjective mystical type experiences. Joe and Kyle emphasize that early studies suggest overlaps with psychedelic states, but they avoid framing Holotropic Breathwork as a cure and instead present it as a powerful tool within a broader healing path. In a culture that often treats psychedelics like quick fixes, this episode makes the case for slow foundations, embodied practice, and honest respect for the risks. By placing Holotropic Breathwork and the other Grof lineage breathwork practices inside a larger conversation about trauma, agency, and community, Joe and Kyle offer a grounded path for anyone who wants to explore non ordinary states in a safer, more skillful way. Learn more about breathwork in the .
/episode/index/show/psychedelicstoday/id/39179990
info_outline
PT 640 - Alexander Beiner - Psychedelics, Culture, and the Games We Play
11/25/2025
PT 640 - Alexander Beiner - Psychedelics, Culture, and the Games We Play
Alexander joins Psychedelics Today to explore how psychedelics, culture, and power shape each other. A writer, facilitator, and co founder of the conference and the media platform , he has spent years thinking about how psychedelic experiences ripple into politics, economics, conflict, and community. In this episode, he and Joe trace the path from early internet forums to today’s psychedelic renaissance, and ask what it would mean to bring a truly psychedelic perspective into our institutions. Beiner is less interested in psychedelics as a niche medical tool and more interested in how they can help us see through destructive cultural “games,” reconnect to our bodies, and relate across deep divides. Early themes with Alexander Beiner The conversation starts with Beiner’s origin story. He describes formative psychedelic experiences as a teenager, and how early access to thinkers like Terence McKenna, Timothy Leary, and the Shulgins led him onto the Grow Report forum and its associated podcasts. From there he launched his own visionary art podcast and eventually co founded Rebel Wisdom, where he focused more broadly on culture, systems, and meaning rather than only on psychedelics. He explains that most of his writing has not been about psychedelic substances, but about a “psychedelic approach” to reality. That means paying attention to complexity, paradox, and relationship, and asking what a psychedelic form of education, politics, or media might look like. He also touches on his documentary “Leviathan,” which looks at breakdowns of trust, disembodiment, and the social forces that pull us away from what is real and relational. Core insights from this conversation In the middle of the episode, the discussion moves into concrete tensions in the current psychedelic resurgence. Topics include: How medicalization can both help and constrain access and the right to alter one’s own consciousness Psychedelic capitalism and the “Moloch” problem of destructive competitive games The risks and potential of psychedelic religions and new spiritual communities Beiner highlights work on ayahuasca circles for Israelis and Palestinians, noting how “we are all one” language can sometimes block necessary truth telling about power and harm. He returns often to embodiment as a key corrective. When people slow down, feel their bodies, and notice what is actually happening in their nervous systems, they can hold disagreement without dehumanizing each other. He also points to emerging work on psychedelics for creativity and problem solving, including stories where psychedelic insights contributed to breakthroughs in science and complex systems thinking. For him, this is one of the most exciting frontiers, because it shifts the story from “fixing a deficit” to “creating something new.” Later discussion and takeaways with Alexander Beiner Later in the episode, Alexander Beiner and Joe talk about , religious freedom, and the need for better checks and balances in emerging psychedelic communities. Beiner stresses that humans are naturally drawn into strong groups and narratives, so the key is not to eliminate “cults” but to spot harmful patterns early and build better accountability. They explore how double binds and mixed messages can create mental distress, and how psychedelics can sometimes resolve these binds by adding new context and perspectives. From there, the conversation turns to third spaces, communitas, and the urgent need for more embodied, in person culture beyond screens, work, and home. Practical takeaways include: Work with psychedelics in ways that reconnect you to your body, not just your ideas Treat medicalization as one path among many, not the only legitimate route Pay attention to group dynamics, power, and accountability in any psychedelic setting Look for ways to bring “psychedelic virtues” like flexibility, curiosity, and compassion into your workplace, family, and community Frequently Asked Questions Who is Alexander Beiner? Alexander Beiner is a writer, facilitator, and co founder of the psychedelic conference Breaking Convention and the media platform Kinos. His work focuses on culture, systems, and how psychedelic perspectives can reshape society. What is Alexander Beiner’s book about? His recent book (discussed in this episode) looks at how psychedelics interact with politics, capitalism, and culture, and asks whether they can help us navigate multiple crises without getting captured by the same destructive games. How does Alexander Beiner view psychedelic medicalization? He sees medicalization as useful but limited. He supports access for people who need it, but worries that a purely medical frame reinforces class divides and hands too much power to psychiatry, instead of centering cognitive liberty and community based use. What is Leviathan in Alexander Beiner’s work? “Leviathan” is his documentary on the breakdown of trust, disembodiment, and large scale systems that pull us away from what is real and relational. It connects mythic images, embodiment, and modern crises of meaning. What is Kinos and how does it relate to Alexander Beiner? KAINOS is Beiner’s Substack based media platform, focused on surfacing novel perspectives and stories about culture, psychedelics, and the future. It extends many of the themes explored in this episode. This episode places Alexander Beiner within the wider psychedelic resurgence as a voice linking inner work to outer systems. For clinicians, researchers, and community members, it offers a rich invitation to think beyond individual healing and ask how psychedelic perspectives might help us transform the cultural games we are playing.
/episode/index/show/psychedelicstoday/id/39171250
info_outline
PT 639 - Evelyn Eddy Shoop PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care
11/21/2025
PT 639 - Evelyn Eddy Shoop PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care
Overview Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science. Early Themes: Injury, OCD, and Choosing Psychiatry Early in the episode, Evelyn Eddy Shoop PMHNP-BC describes how multiple season ending injuries in college and serious mental health stressors in her family pushed her to rethink her life path. Originally pre vet, she stepped away from veterinary medicine after realizing she could not tolerate that environment. During a semester off for surgery and mental health, she completed intensive outpatient treatment and family therapy. That time showed her how powerful psychological work could be. It also reawakened a long standing curiosity about the brain, consciousness, and human experience. This led her to switch her major to psychology and later pursue psychiatric mental health nurse practitioner training at the University of Pennsylvania. At Penn, she felt supported academically and personally. Her interest in psychedelics grew as she realized that standard OCD treatments and high dose SSRIs were not giving her the level of functioning or happiness she knew was possible. Core Insights: Psilocybin Trials, Qualitative Data, and Clinical Skepticism In the middle of the episode, Eddy shares the story of finding a psilocybin trial on ClinicalTrials.gov just as she was about to start ketamine therapy. She received placebo first, then open label psilocybin, and describes the dosing day as one of the hardest days of her life, with benefits that emerged slowly over months through integration. She uses her experience to highlight why qualitative data matters. Numbers alone cannot capture the depth of a psychedelic journey or the slow unfolding of meaning over time. She argues that subjective stories, even difficult ones, are essential for clinicians, researchers, and policymakers. Key themes include: The central role of integration support in turning a crisis level session into lasting growth How trial environments on inpatient psychiatric units can feel like prison instead of healing spaces The limits of double blind placebo trials when participants become desperate for active treatment The need for more nuanced language around psychosis and psychedelic harms Eddy also addresses skepticism in psychiatry. Many providers fear substance induced psychosis and feel uneasy with medicines whose mechanisms are not fully understood. She suggests that more lived experience stories and careful education can help bridge that gap. Later Discussion and Takeaways In the later part of the episode, Eddy and Joe discuss harm reduction, ketamine risks, and how poorly designed systems can create harm even when the medicine itself is helpful. Eddy describes being treated as “just another psych patient” once the research team left for the day, including being denied basic comforts like headache relief after an emotionally intense session. She calls for: More humane hospital and research environments Required psychedelic education in psychiatric training Honest, nonjudgmental conversations about substance use with patients Stronger public education for students and festival communities Eddy also invites listeners in Wilmington, Delaware and nearby regions to connect if they need a psychiatric mental health nurse practitioner for psychedelic related research. She hopes to bring her lived experience and clinical skills into the emerging field as psilocybin and other treatments move toward approval. Frequently Asked Questions Who is Evelyn Eddy Shoop PMHNP-BC? She is a psychiatric mental health nurse practitioner trained at the University of Pennsylvania, a former Division I athlete, and a psilocybin trial participant who now advocates for more humane and data informed psychedelic care. What did Eddy learn from her psilocybin clinical trial experience? She learned that the hardest sessions can lead to deep change when integration support is strong and when there is time to unpack insights, rather than rushing to rate symptoms on a scale. Why does she care so much about qualitative data in psychedelic research? Eddy believes that numbers cannot capture the full human impact of psychedelic therapy. Stories show how people actually live with their disorders and integrate change, which is vital for ethical practice and policy. How does she view psychedelic harms and psychosis risk? She acknowledges real risks, especially for people with certain histories, but also notes that some psychotic experiences are not distressing. She calls for more precise language, better containers, and honest harm reduction education. What role does a psychiatric nurse practitioner like Evelyn play in psychedelic care? Practitioners like Evelyn can assess risk, prescribe within legal frameworks, provide preparation and integration, and help bridge the gap between traditional psychiatry and emerging psychedelic therapies. Psychedelic care is evolving fast, and this episode shows why voices like Evelyn Eddy Shoop PMHNP-BC are essential in the current psychedelic resurgence. Her blend of lived experience, clinical training, and critical thinking points toward a future where data and story, safety and possibility, can finally grow together.
/episode/index/show/psychedelicstoday/id/39123270
info_outline
PT 638 - Dr Jason Konner - Psychedelic Oncologist
11/18/2025
PT 638 - Dr Jason Konner - Psychedelic Oncologist
In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at to devote himself to the emerging intersection of cancer care and psychedelics. Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply , though he didn’t have that language for it at the time. A chance moment in a yoga class, overhearing someone say “ retreat” just before he was scheduled for hernia surgery, became the turning point. Within a week, he was in the jungle. That first week with ayahuasca, followed later by work with mushrooms, “absolutely transformed” his life. His fear of death lifted. The burnout he hadn’t even recognized in himself was both revealed and relieved. When he returned to his practice, Konner describes feeling like he suddenly had a “superpower”: he could stay present, connected, and compassionate with patients facing advanced disease without collapsing under the emotional weight. He and Joe explore what this third path looks like: not the classic binary between either hardening and distancing as self-protection, or staying open-hearted and getting shattered. Instead, psychedelics helped him hold deep relationship with patients and families while maintaining inner stability and meaning. This opened space for authentic conversations about spirituality, fear, grief, and what it means to live with (or die from) cancer. From there, Dr Konner zooms out to critique the broader oncology system: The lack of training and support for oncologists around their own emotional and existential load, How little space there is for relational work even though it’s central to healing, Why many support groups and standard psychiatric approaches (like reflexively prescribing SSRIs) often miss the mark for people dealing with cancer, How caregivers, partners, family members, and others are deeply affected but rarely truly supported. Joe and Jason then dig into psychedelics and oncology as a frontier: easing existential distress in patients with terminal cancer, the neglected suffering of caregivers, the potential role of psychedelics in helping people relate differently to death, and what it might mean for ICU use, aggressive end-of-life interventions, and overall healthcare costs if more people could make decisions from a place of peace rather than terror. Dr Konner also shares a striking ovarian cancer case that hinted at powerful immune changes after shamanic work, and why he believes we need new research paradigms that can honor the integrity of retreat and ceremonial settings while still learning from them. Finally, he talks about his early-stage project, , and his hope that the first wave of change starts with clinicians themselves becoming more psychedelic-literate—and, where appropriate, doing their own inner work—so better options can eventually reach the people who need them most.
/episode/index/show/psychedelicstoday/id/39081895
info_outline
PT 637 - Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration
11/11/2025
PT 637 - Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration
Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused on ketamine-assisted therapy while preparing for MDMA’s eventual approval. She also co-founded a sliding-scale KAP nonprofit (now Alchemy Community Therapy Center), co-edited Integral Psychedelic Therapy, and is helping to launch the International Alliance of MDMA Practitioners. In this episode From counterculture to mainstream: What’s been gained—and lost—as psychedelics scaled. Accessibility vs. corporatization: Why cutting corners (prep/integration, therapeutic time) undermines outcomes and safety. “Myth of the magic pill”: Psychedelics can catalyze change, but healing is an ongoing process anchored by integration. What good care looks like: Preparation → medicine sessions → robust integration, individualized cadence, and adding bodywork and functional medicine to address gut-brain links, mineral status, sleep, and somatic tension. Ketamine realities: Differences between psycholytic (talk-forward) and psychedelic (eyes-closed, inner-directed) dosing; why some need multiple sessions to build relationship with the medicine; risks of mail-order models (high dosing, poor screening/support), daily prescribing, addiction potential, cystitis, and safety concerns. Sitting, not guiding: The therapist’s task is to follow the client’s process; intervene sparingly and with consent—especially in trauma work where attuned co-regulation is essential. Multiple access pathways: Support for regulated clinical care and community, peer, and ceremonial models—paired with education and harm reduction (Zendo’s SIT peer training and new crisis-responder training). The MDMA pause: Initial devastation at the FDA decision gave way to seeing benefits: time to strengthen ethics, accountability, training standards, and to temper hype-driven investment. Pace and ethics: Lessons from burnout; moving at the speed of trust; exploring “psychedelic business models” (stakeholder focus, distributed decision-making, employee ownership, public benefit structures). Resources & organizations mentioned Takeaway: Thoughtful preparation, right-sized dosing, and committed integration—held within ethical, community-minded systems—turn powerful experiences into durable change.
/episode/index/show/psychedelicstoday/id/38994895
info_outline
PT 636 - Dr. Ros Watts – Building Communities and Connection
11/04/2025
PT 636 - Dr. Ros Watts – Building Communities and Connection
Clinical psychologist joins to share insights from her decade of work with and her evolving focus on community-based integration. As the former Clinical Lead for , Dr. Watts witnessed how psychedelic experiences can foster profound feelings of — to self, others, and nature — yet also how that connection can fade without ongoing support. In this conversation, she reflects on what years of research have taught her about connectedness as both a healing mechanism and a human need. She explores how can transform fleeting psychedelic breakthroughs into lasting change, and why community is not just a “nice-to-have,” but a core part of psychological and ecological resilience. Dr. Ros Watts also discusses her “Twelve Trees” framework — a nature-inspired model for personal and collective growth that helps participants translate insight into action through values, embodiment, and mutual care. Her current project, (Accept, Connect, Embody, Restore), is a 13-month, co-created journey that guides people in weaving psychedelic insights into everyday life while deepening relationships with self, others, and the living world. Named among the and , Dr. Watts continues to advocate for integration, harm-reduction, and inclusion in the psychedelic space. Together, we explore what sustainable healing really means, how organizations can embody the same principles they teach, and how the psychedelic movement can root itself in care, connection, and community. Learn more about ACER Integration: Find Dr Ros Watt's webpage here.
/episode/index/show/psychedelicstoday/id/38908165
info_outline
PT 635 - Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher
10/28/2025
PT 635 - Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher
Artist, builder, and podcast host Jennifer Espenscheid joins Joe Moore for a rich conversation on creativity, process, and the spiritual dimensions of making art. Drawing from her South Dakota roots and large-scale works like Luciferia, Jennifer reflects on the blend of grit, intuition, and trust that guides her artistic life. She discusses how psychedelics have served as a tool for clarity and healing rather than direct creation of art, helping her dissolve patterns and reconnect to innate creativity. They explore how events like Burning Man catalyze inspiration, why intention and integration matter as much as vision, and the discipline of “earning your dopamine”—staying self-motivated instead of chasing external highs. Jennifer shares lessons about gestation, patience, and protecting early ideas before they’re ready to be seen. Together they examine creativity as a human birthright and art as a daily practice of attention and renewal. “By being human, you are intrinsically creative. Psychedelics help me clear the noise so I can actually hear and honor that.” Links
/episode/index/show/psychedelicstoday/id/38813100
info_outline
PT 634 - Brad Adams - LAMPS
10/21/2025
PT 634 - Brad Adams - LAMPS
Brad Adams — LAMPS (Los Angeles Psychedelic Society) joins Kyle to trace his path from PhD researcher to community builder. Brad shares how early work in AIDS, Alzheimer’s, gerontology, and cancer research primed him to notice Harbor-UCLA’s psilocybin pilot for stage-4 cancer patients with death anxiety—where the strongest mystical experiences correlated with profound death acceptance. Teaming with Dennis McKenna, he ran an ayahuasca pilot in Peru and presented findings at Psychedelic Science 2017. From there, Brad founded LAMPS: first as research meetups at UCLA, then as a thriving hub hosting speakers and, ultimately, an L.A. psychedelic conference. He previews the November 1 event at Above the Block in West L.A.: daytime panels on cannabis, preparation/integration, and music & psychedelics; a vendor hall; and a “Healing Lounge” with bodywork, astrology, human design, and more—closing with a late-night dance party featuring David Starfire. Brad offers grounded advice for starting local communities (begin small, meet regularly, curate safe dialogue, and moderate firmly), and reflects on platform friction around psychedelics. The conversation widens to DMTx (extended-state DMT), entity encounters, and what humble, relational curiosity can reveal—then to Wetiko, IFS, and the hero’s journey as frames for keeping hope alive in turbulent times. A candid and practical tour of research, resilience, and real-world community building.
/episode/index/show/psychedelicstoday/id/38732050
info_outline
PT 633 - Dreamshadow - Life and Breath
10/15/2025
PT 633 - Dreamshadow - Life and Breath
In this episode, Kyle and Joe sit down with filmmaker Mustapha Khan and Dreamshadow’s Elizabeth & Lenny Gibson to explore Life and Breath—a new documentary immersing viewers in the experience and community of Holotropic Breathwork. We talk about why Mustapha was drawn to Dreamshadow, the film’s cinéma vérité approach that places you “in the room,” and how years of facilitation informed what became both an archival record and a living portrait of transformation. Elizabeth and Lenny reflect on 35+ years of holding space, the role of curiosity over agenda, and why genuine community—not just catharsis—is central to lasting growth. Kyle and Joe share personal reactions from a Breckenridge screening, the emotions it stirred, and how this work has shaped Psychedelics Today. We close on hope, relationship, and the power of gathering to remember who we are. Keep an eye out for upcoming screenings and Q&As with the team behind Life and Breath. won first place at the Psychedelic Film and Music Festival!
/episode/index/show/psychedelicstoday/id/38593450